Instruction for use: Galavit

Dosage form: Powder for solution for intramuscular administration; Substance-powder; Suppositories rectal; Sublingual tablets

Active substance: Aminodihydrophthalasindionum natrium

ATX

L03 Immunostimulants

Pharmacological groups

Immunomodulating and anti-inflammatory agent [Other different drugs]

Immunomodulating and anti-inflammatory agent [Other non-narcotic analgesics, including non-steroidal and other anti-inflammatory drugs]

Immunomodulating and anti-inflammatory agent [Other immunomodulators]

The nosological classification (ICD-10)

A04.9 Bacterial intestinal infection, unspecified: Bacterial intestinal infection; GI tract infections; Infections of intestinal bacterial; Digestive tract infections; Infectious and inflammatory diseases of the digestive tract; Infectious Disease of the GI tract; Infection of the intestine; Intestinal infection; Acute infectious disease of the digestive tract; Acute intestinal disease with colon lesions; Acute intestinal infection

A09 Diarrhea and gastroenteritis of allegedly infectious origin (dysentery, bacterial diarrhea): Bacterial diarrhea; Bacterial dysentery; Bacterial infections of the digestive tract; Bacterial gastroenteritis; Diarrhea bacterial; Diarrhea or dysentery of amoebic or mixed etiology; Diarrhea of infectious genesis; Diarrhea on the background of antibiotic therapy; Traveler's Diarrhea; Travelers diarrhea due to changes in diet and habitual diet; Diarrhea due to antibiotic therapy; Dysenteric bacteriocarrier; Dysenteric enteritis; Dysentery; Dysentery bacterial; Dysentery mixed; Gastrointestinal infection; GI tract infections; Infectious diarrhea; Infectious Disease of the GI tract; Infection of the gastrointestinal tract; Infection of the biliary tract and gastrointestinal tract; GI tract infection; Summer diarrhea; Nonspecific acute diarrhea of infectious nature; Nonspecific chronic diarrhea of infectious nature; Acute bacterial diarrhea; Acute diarrhea in food poisoning; Acute dysentery; Acute bacterial gastroenteritis; Acute gastroenterocolitis; Acute Enterocolitis; Subacute dysentery; Diarrhea chronic; Refractory diarrhea in AIDS patients; Staphylococcal enteritis in children; Staphylococcal enterocolitis; Toxic diarrhea; Chronic dysentery; Enteritis; Enteritis infectious; Enterocolitis

A41.8 Other specified septicemia: Fungal sepsis; Abdominal sepsis; Sepsis; Sepsis burn; Surgical sepsis; Sepsis tonsilogenous

A46 erysipelas: erysipelas

A48.3 Toxic shock syndrome: Bacteremic shock; Infectious-toxic shock; Intoxication syndrome; Toxico-infectious shock; Toxic shock; Chronic intoxication in diseases of the digestive tract; Chronic intoxication in gastrointestinal infections; Endotoxin shock

A56.0 Chlamydial infections of the lower tract of the genito-urinary tract: Chlamydial balanoposthitis; Chlamydial prostatitis; Cervicitis of chlamydial etiology

A56.2 Chlamydial infection of the urogenital tract, unspecified: Chlamydial urethritis; Urogenital chlamydia; Chlamydial gynecological infections; Cervicitis of chlamydial etiology

A59.0 Urogenital Trichomoniasis: Trichomonas Colpitis; Trichomonas infection of the urinary tract; Vaginal trichomoniasis; Trichomonal vaginitis; Trichomonas inflammation of the vagina; Trichomonas inflammation of the urinary tract; Trichomonas vaginitis; Trichomonal Urethritis; Trichomonatal balanoposthitis; Trichomonas vulvovaginitis; Trichomonal Urethritis; Urethritis caused by Trichomonas; Trichomonas urethritis; Vaginitis due to Trichomonas; Trichomoniasis of the genitourinary system; Trichomonas colpitis; Trichomonas infection of the urogenital organs

B00 Infections caused by the herpes simplex virus [herpes simplex]: Herpes simplex; Herpes virus; Herpes simplex virus; Herpes simplex virus type I and II; HSV; Herpes; Herpes simplex / herpes simplex /; Herpes lips; Herpes simplex; Herpes in patients with immunodeficiency; Labial herpes; Acute herpetic disease of the mucous membranes; Herpes simplex; Herpes simplex skin and mucous membranes; Herpes simplex with skin and mucous membrane damage; Recurrent herpes; Urogenital herpetic infection; Chronic recurrent herpesvirus infection; Herpes-viral infections of various localizations

B19 Viral hepatitis, unspecified: Anemia without hepatitis; Viral hepatitis; Viral hepatitis in children; Infection of the liver; Acute liver infection

B34 Viral infection of unspecified site: Viral respiratory tract infections; Infections viral; Viral infection; Viral infections

B97.7 Papillomavirus: Human papillomavirus; Asymptomatic selection of human papillomavirus; Papillomavirus infection; The papilloma virus; Upper respiratory tract papillomatosis; Papillomovirus infection; Human papillomaviruses

D26 Other benign neoplasms of the uterus: Fibromyoma of the uterus; Myoma; Uterine fibroids; Fibromyoma; Myoma of the uterus; Fibrrios; Meigs syndrome; Tumors of the uterus

D84.9 Unspecified Immunodeficiency: Pneumonia in immunodeficient states; Autoimmune disease; Autoimmune diseases; Severe immunodeficiency; immune deficiency; Immunodeficiency; immunodeficiency diseases; Immunodeficiency states due to surgery; Immunotherapy for cancer; Immunomodulation; Infections in patients with weakened immune systems; Correction of immune deficiency; Correction of immunodeficiencies; Correction of a weakened immune system; Correction of a weakened immunity in immunodeficient states; Violation of immunity; Violation of the immune status; Immune System Disorders; Primary immunodeficiency; Maintaining immunity; Lowering the body's defenses; Lowering the immunity; Lowering the immunity of colds and infectious diseases; The decrease of the immune status; Lowered resistance to infections; Lowered resistance to infections and colds; Lowered resistance; Immunosuppression; Predisposition to colds; acquired immune deficiencies; Radiation immunodeficiency; The development of immunodeficiency; Immune dysfunction syndrome; immunodeficiency syndrome; primary immunodeficiency syndrome; Reducing the body's defenses; Immunosuppression; Reduced immune defense; Reducing local immunity; Reducing the total body resistance; The decrease in cell-mediated immunity; Reduced resistance to infections in children; Reducing the body's resistance; Reduced resistance; reduced immunity; Status immunodeficiency; Stimulation of the processes of nonspecific immunity; Heavy selective secondary immunodeficiency; immunity Oppression; Primary immunodeficiency

E63 Physical and mental overloads: Recovery period for athletes; Restoration of physical fitness of sportsmen; High psychoemotional load; High psychoemotional loads; High physical activity; Continuous overload and voltage; Prolonged physical and mental loads; Prolonged physical activity; Intellectual Loads; Intensive mental and physical activity; Intensive physical activity; Tense mental activity; Impairment of mental performance; Inadequate nutrition for physical and mental overloads; Nervous and physical overstrain; Nervous overvoltage; Nervous overwork; Nervously-emotional overload; Increased mental and physical load; Increased mental load; Increased physical activity; Increased physical and mental stress; Increased physical and psychoemotional load; Increased physical and emotional stress; Increased physical activity; Increased psychoemotional loads; Increased physical activity; Decreased mental performance; Decrease physical and mental performance; Reduced performance; Mental and physical exhaustion; Psychological and physical stress; Psycho-emotional overload; Psychoemotional stress; Psychoemotional Disorder; Physical overstrain syndrome; Decreased mental performance; Reduced tolerability of psychophysical loads; Reduced mental performance; State of fatigue; Mental and psychoemotional load; Mental and physical load; Mental and physical overload; Mental and physical fatigue; Mental load; Mental and physical exhaustion.; Mental and physical stress; Mental and physical overstrain; Mental and physical exhaustion; Mental overload; Increased physical and mental stress; Physical and mental load; Physical and mental performance; Exercise stress; Physical overload; Physical and emotional overloads; Physical overload; Physical and mental stress; Physical and mental stress; Physical overstrain; Physical loads; Chronic fatigue; Chronic physical overstrain; Excessive physical and mental stress; Excessive physical and mental stress; Excessive physical activity; Excessive mental and physical stress; Extreme physical activity; Physical exercise

F06.6 Organic emotionally labile [asthenic] disorder: Somatogenic depression; Somatogenic psychosis

F10 Mental and behavioral disorders due to alcohol use: Alcoholic adynamic depression; Depressive and anxious-depressive state in patients with alcoholism; Behavioral and postabstinctive disorder in alcohol dependence

F10.3 Abstinence: Alcohol withdrawal syndrome; Abstinence syndrome; Abstinence syndrome with alcoholism; Abstinence; Alcohol abstinence; Alcohol withdrawal status; Alcohol withdrawal syndrome; Postabstinctive disorder; Post-abstinence condition; Hangover syndrome; Abstinence syndrome; Alcohol abstinence syndrome; Alcohol withdrawal syndrome; Abstinence condition

F11 Mental and behavioral disorders due to use of opioids: heroin addiction; heroin addiction; Diagnosis of opioid dependence; Dependence on opioids; morphine withdrawal; Opiate withdrawal; opium addiction; Opioid dependence; Opioid addiction; Behavioral disorder and postabstinentnom for drug dependence

F12 Mental and behavioral disorders caused by cannabinoid use: Dependence on cannabino type substances; Behavioral and postabstinctive disorder in drug dependence

F45 Somatoform disorders: Psychosomatic disorder; Psychosomatic disorders; Psychosomatic diseases; The state of excitement in somatic diseases; Functional psychosomatic disorders of the cardiovascular system

F48 Other neurotic disorders: Neurosis; Neurological diseases; Neurotic disorders; Neurotic condition; Psychoneurosis; Anxious-Neurotic Conditions; Chronic neurotic disorders; Emotional reactive disorders

F48.0 Neurasthenia: Asthenic form of neurasthenia; Asthenoneurotic disorder; Astheno-neurotic state; Flu of young workaholics; Influenza yuppies; Neurasthenic disorders; Neurasthenic conditions; Neurasthenic syndrome

G90 Disorders of autonomic [autonomous] nervous system: angiodystonia; vasovegetative manifestations; vasomotor dystonia; vegetative dystonia; autonomic dysfunction; vegetative lability; Vegetative-vascular disorders; autonomic dysfunction; vasoneurosis; Vegetative-vascular dystonia; vegetative-vascular disorders; Vegetative-vascular disorders; Dystonia vegetovascular; Dystonia neurocirculatory; neuro disorder; Cardiopsychoneurosis; Neurocirculatory dystonia of hypertensive type; Primary neurovegetative syndrome; The syndrome of vegetative dystonia

H66.9 Otitis media, unspecified: Chronic otitis media; Otitis; Average otitis media; Middle ear infection; Otitis media in children

J02 Acute pharyngitis: Inflammation of the nasopharynx; Inflammatory disease of the oropharynx; Inflammatory process of pharynx; Infectious diseases of ENT organs; Sore Throat Infection; Exacerbation of inflammatory diseases of the pharynx and oral cavity; Pharyngitis; Pharyngitis acute; Pharyngolaryngitis

J02.9 Acute pharyngitis, unspecified: Purulent pharyngitis; Acute rhinopharyngitis; Lymphonodular pharyngitis

J06 Acute upper respiratory tract infections of multiple and unspecified locations: Frequent colds of viral diseases; Infections of ENT organs; Acute respiratory illness of influenza nature; Pain for colds; Acute catarrhal disease; Cold; Colds; Colds; Respiratory infection; Seasonal catarrhal disease; Seasonal colds; Pain in infectious and inflammatory diseases of the upper respiratory tract; Bacterial infections of the upper respiratory tract; Bacterial infections of the respiratory system; Viral respiratory disease; Viral respiratory tract infections; Inflammatory disease of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract; Inflammatory diseases of the upper respiratory tract with difficult to separate sputum; Inflammatory respiratory disease; Secondary infections for colds; Difficult sputum separation in acute and chronic respiratory diseases; Upper respiratory tract infections; Infections of the upper respiratory tract; Respiratory tract infections; Respiratory and lung infections; Infectious-inflammatory diseases of the upper respiratory tract; Infectious-inflammatory diseases of the upper respiratory tract and ENT organs; Infectious-inflammatory diseases of the upper respiratory tract in adults and children; Infectious-inflammatory diseases of the upper respiratory tract; Infectious inflammation of the respiratory tract; Respiratory tract infection; Qatar upper respiratory tract; Catarrh of the upper respiratory tract; Catarrh of the upper respiratory tract; Catarrhal phenomena from the upper respiratory tract; Cough in diseases of the upper respiratory tract; Cough for colds; ARVI; ARI; ARI with phenomena of rhinitis; Acute respiratory infection; Acute infectious-inflammatory disease of the upper respiratory tract; Acute respiratory disease; Persecution in the throat or nose; Respiratory and viral infections; Respiratory diseases; Respiratory infections; Recurrent respiratory tract infections; Secondary infections with influenza; Influenza states; Feverish conditions for influenza

J18 Pneumonia without specification of pathogens: Alveolar pneumonia; Community-acquired pneumonia atypical; Community-acquired pneumonia non-pneumococcal; Pneumonia; Inflammation of the lower respiratory tract; Inflammatory lung disease; Shared pneumonia; Respiratory and lung infections; Infections of the lower respiratory tract; Cough with inflammatory diseases of the lungs and bronchi; Croupous pneumonia; Nosocomial pneumonia; Exacerbation of chronic pneumonia; Acute community-acquired pneumonia; Acute pneumonia; Focal pneumonia; Pneumonia abscessing; Pneumonia bacterial; Pneumonia croupy; Pneumonia of focal; Pneumonia with difficulty in sputum discharge; Pneumonia in AIDS patients; Pneumonia in children; Septic pneumonia; Chronic Obstructive Pneumonia; Chronic pneumonia; Lymphoid interstitial pneumonia

J31.2 Chronic pharyngitis: Pharyngitis chronic; Exacerbation of inflammatory diseases of the pharynx and oral cavity; Hypertrophic pharyngitis; Inflammatory process of pharynx; Sore Throat Infection; Infectious-inflammatory diseases of the pharynx; Infectious-inflammatory diseases of the oral cavity and pharynx; Atrophic pharyngitis

J35.0 Chronic tonsillitis: chronic tonsillitis; Inflammatory diseases of the tonsils; Angina chronic; Chronic hypertrophic tonsillitis; Tonsillar angina

J35.2 Hypertrophy of adenoids: Adenoids; Adenoiditis

J35.9 Chronic disease of tonsils and adenoids, unspecified

J39.9 Disease of upper respiratory tract, unspecified: Mechanical irritation of mucosa of upper respiratory tract; Acute respiratory disease; Recurrent infections of ENT organs; Chronic infection of the upper respiratory tract; Chronic infections of ENT organs; Infections of ENT organs

J40 Bronchitis not specified as acute or chronic: Asthmatic bronchitis; Allergic bronchitis; Bronchitis allergic; Asthmatic bronchitis; Rhinotraheobronchitis; Asthmatic bronchitis; Bacterial bronchitis; Bronchitis; Bronchitis of the smoker; Bronchitis of smokers; Inflammation of the lower respiratory tract; Disease of the bronchi; Qatar smoker; Cough smokers; Cough with inflammatory diseases of the lungs and bronchi; Disturbance of bronchial secretion; Impaired bronchial function; Acute tracheobronchitis; Subacute bronchitis; Tracheobronchitis; Chronic lung diseases

J86 Pythorax: Purulent pleurisy; Destruction of lungs bacterial; Pleurisy purulent; Empyema; Empyema of the lungs; Empyema of the lung; Empyema of the pleura

J98.8 Other specified respiratory disorders: Recurrent respiratory infections

K05.6 Periodontal disease, unspecified: Inflammatory-dystrophic forms of periodontitis; Periodontal disease; Parodontopathy; Erosive-ulcerative periodontal disease; Erotic-ulcerative periodontal lesions; Youthful periodontitis

K12 Stomatitis and Related Losses: Bacterial stomatitis; Inflammatory diseases of the oral cavity; Inflammatory diseases of tissues of the oral cavity; Inflammatory processes in the oral cavity; Fungal diseases of the mouth; Fungal infections of the oral cavity; Fungal infections and inflammatory diseases of the mouth; Diseases of the mouth; Infectious-inflammatory disease of the oral cavity; Exacerbation of inflammatory diseases of the pharynx and oral cavity; Stomatitis; Angular stomatitis; Chronic recurrent stomatitis; Ulcerative necrotic diseases of the oral mucosa; Ulcerative necrotic diseases of the oral mucosa; Ulcerative necrotic lesions of the oral mucosa; Ulcerative necrotic gingivostomatitis; Ulcerative stomatitis; Erosive-ulcerative lesion of the oral mucosa; Erosive-ulcerative lesions of the mucous membrane of the oral cavity; Erotic mucous membrane of the oral cavity; Recurrent ulcerative stomatitis

K13.7 Other and unspecified oral white lesion: Aspirin burn of the oral mucosa; Gum pain when wearing dentures; Inflammation of the mouth; Inflammation of the oral mucosa after radiation therapy; Inflammation of the oral mucosa after chemotherapy; Inflammation of the oral mucosa; Inflammation of the mucous membranes of the mouth; Inflammatory diseases of the oral cavity; Inflammatory process of pharynx; Disease of the oral mucosa; Injuries to the oral cavity and larynx; Injuries of the oral mucosa; Trophic diseases of the oral mucosa; Trophic diseases of the oral mucosa; Erosive-ulcerative periodontal disease; Erosive-ulcerative lesion of the oral mucosa; Erotic mucous membrane of the oral cavity; Erotic-ulcerative periodontal lesions; Erosive-ulcerative lesions of the mucous membrane of the oral cavity; Radio-epileleitis; Irritation from dentures; Irritation of the oral mucosa with dentures and braces; Oral cavity; When wearing dentures

K25 Stomach ulcer: Helicobacter pylori; Pain syndrome with gastric ulcer; Pain syndrome with peptic ulcer of stomach and duodenum; Inflammation of the gastric mucosa; Inflammation of the mucosa of the gastrointestinal tract; Benign ulcer of the stomach; Disease of the stomach and duodenum, associated with Helicobacter pylori; Exacerbation of gastroduodenitis against ulcer disease; Exacerbation of peptic ulcer; Exacerbation of gastric ulcer; Organic GI disease; Peptic ulcer of the stomach and duodenum; Postoperative Stomach Ulcer; Recovering ulcers; Symptomatic Stomach Ulcers; Chronic inflammatory disease of the upper gastrointestinal tract associated with Helicobacter pylori; Helicobacter pylori eradication; Erosive-ulcerative lesions of the stomach; Erosive lesions of the stomach; Erosion of the gastric mucosa; Peptic Ulcer; Stomach ulcer; Stomach ulcer; Ulcerative lesions of the stomach; Symptomatic ulcers of the stomach and duodenum

K26 Ulcer of duodenum: Pain syndrome with duodenal ulcer; Pain syndrome with peptic ulcer of stomach and duodenum; Disease of the stomach and duodenum, associated with Helicobacter pylori; Exacerbation of peptic ulcer; Exacerbation of duodenal ulcer; Peptic ulcer of the stomach and duodenum; Recurrence of duodenal ulcer; Symptomatic ulcers of the stomach and duodenum; Helicobacter pylori eradication; Erosive-ulcerative lesions of the duodenum; Erosion-ulcerative duodenal lesions associated with Helicobacter pylori; Erosive lesions of the duodenum; Peptic ulcer disease of the duodenum; Ulcerative duodenal lesions

K35 Acute appendicitis

K65 Peritonitis: Abdominal infection; Intra-abdominal infections; intra-abdominal infections; Diffuse peritonitis; abdominal Infections; Infections of the abdominal cavity; The infection of the abdominal cavity; The infection of the gastrointestinal tract; Spontaneous bacterial peritonitis

L02 Abscess of skin, furuncle and carbuncle: Furuncle of external auditory canal; Furuncle of the auricle; Furuncles; Abscess; Abscess of skin; Carbuncle; Carbuncle skin; Furuncle; Skin furuncle; Furunculosis Chronic recurrent furunculosis

M86.6 Other chronic osteomyelitis: Chronic osteomyelitis; Osteomyelitis chronic

N34 Urethritis and urethral syndrome: Urethral buzhirovanie; Gonococcal urethritis; Urethrocystitis; Gonorrheic urethritis; Urethritis; Non-gonococcal urethritis; Negative urethritis; Lesion of the urethra; Acute gonococcal urethritis; Acute gonorrhea urethritis; Acute urethritis; Infection of the urethra; Bacterial nonspecific urethritis; Bacterial urethritis

N39.0 Urinary tract infection without established localization: Fungal infections of the urinary tract; Asymptomatic bacteriuria; Bacterial infections of the urinary tract; Bacterial infections of the urinary tract; Bacterial infections of the genitourinary system; Bacteriuria; Bacteriuria asymptomatic; Bacteriuria chronic latent; Asymptomatic bacteriuria; Asymptomatic massive bacteriuria; Inflammatory urinary tract disease; Inflammatory urinary tract disease; Inflammatory diseases of the bladder and urinary tract; Inflammatory diseases of the urinary system; Inflammatory diseases of the urinary tract; Inflammatory diseases of the urogenital system; Fungal diseases of the urogenital tract; Urinary Tract Infections; Urinary Tract Infections; Infections of the urinary system; Urinary tract infections; Urinary Tract Infections; Urinary tract infections caused by enterococci or mixed flora; Urinary tract infections uncomplicated; Urinary tract infections complicated; Infections of the urogenital system; Infections urogenital; Infectious diseases of the urinary tract; Urinary Tract Infection; Urinary tract infection; Urinary system infection; Urinary tract infection; Urinary tract infection; Infection of the urogenital tract; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated urinary tract infections; Uncomplicated infections of the genitourinary system; Exacerbation of chronic urinary tract infection; Retrograde kidney infection; Recurrent urinary tract infections; Recurrent urinary tract infections; Recurrent infectious diseases of the urinary tract; Mixed urethral infections; Urogenital infection; Urogenital Infectious-Inflammatory Disease; Urogenital mycoplasmosis; Urologic disease of infectious etiology; Chronic urinary tract infection; Chronic inflammatory diseases of the pelvic organs; Chronic urinary tract infections; Chronic infectious diseases of the urinary system

N41.0 Acute prostatitis: Acute bacterial prostatitis; Urethroprostatitis; Chlamydial prostatitis

N41.1 Chronic prostatitis: Recurrent prostatitis; Chronic bacterial prostatitis; Chronic abacterial prostatitis; Chronic bacterial prostatitis; Chlamydial prostatitis; Exacerbation of chronic prostatitis; Chronic abacterial prostatitis

N49 Inflammatory diseases of male genital organs, not elsewhere classified: Bacterial diseases of urogenital tract; Bacterial infections of the genitourinary system; Sexually Transmitted Infections in Men; Infections urogenital; Infectious diseases of the reproductive system; Infectious diseases of genital organs; Chronic inflammatory diseases of the pelvic organs; Infections of the male genital tract

N70 Salpingitis and oophoritis: Adnexitis; Inflammatory diseases of female genitalia; Inflammatory diseases of female genital organs; Infection of the genitals; Oophoritis; Acute adnexitis; Salpingitis; Salpingo-oophoritis; Chronic inflammatory diseases of the ovaries; Inflammation of the ovaries

N70.0 Acute salpingitis and oophoritis: Acute salpingo-oophoritis

N70.1 Chronic salpingitis and oophoritis: Chronic salpingo-oophoritis; Chronic adnexitis

N71 Inflammatory diseases of the uterus other than the cervix: Intrauterine infections; Inflammatory diseases of female genitalia; Inflammatory diseases of female genital organs; Infection of the genitals; Chronic endometriometritis; Chronic inflammatory disease of the uterus; Endometritis; Endometriometry

N73.9 Inflammatory diseases of female pelvic organs, unspecified: Urogenital tract infections; Abscess of pelvic organs; Bacterial diseases of the urogenital tract; Bacterial infections of the genitourinary system; Bacterial infections of the pelvic organs; Intraluminal infections; Inflammation in the area of throat of the uterus; Inflammation of the organs of the small pelvis; Inflammatory disease of the pelvic organs; Inflammatory gynecological diseases; Inflammatory diseases of female pelvic organs; Inflammatory diseases of the pelvic organs; Inflammatory diseases of pelvic organs; Inflammatory infections in the pelvis; Inflammatory processes in the pelvis; Gynecological infection; Gynecological infections; Gynecological infectious diseases; Pyoinflammatory diseases of the pelvic organs; Infections of female genital organs; Infections of the pelvic organs in women; Infections of the pelvic organs; Infectious diseases of the reproductive system; Infectious diseases of genital organs; Infection of female genital organs; Metritis; Acute infection of female genital organs; Acute pelvic inflammatory disease; Tubo-ovarian inflammation; Chlamydial gynecological infections; Chronic inflammatory diseases of the pelvic organs; Chronic inflammatory diseases of appendages; Chronic infections of female genital organs; Pelvic infection

R53 Malfunction and fatigue: Asthenic disorders; Asthenic conditions; Asthenic phenomena; Asthenic syndrome; Asthenic disorder; Asthenic state; Asthenic phenomenon; Asthenia; Astheno-adynamic subdepressive state; Asthenovegetative symptoms; Asthenic-autonomic symptomatology; Asthenic autonomic disorder; Asthenodepressive disorder; Astheno-depressive disorder; Asthenodepressive state; Astheno-depressive state; Asthenoneurotic disorder; Astheno-neurotic state; Fast fatiguability; Flu of young workaholics; Influenza yuppie; Diabetic asthenia; Exhaustion of the nervous system; Exhaustion physical; Malaise; Nervous depletion with depression; General mental fatigue; General physical fatigue; General malaise; Pathological fatigue; Increased fatigue; Mental fatigue; Mental exhaustion; Astenovegetative Syndrome; Chronic Fatigue Syndrome; Decrease in total activity; The state of increased fatigue; Conditions of increased fatigue; Mental fatigue; Prostration; Fatigue; Fatigability; Physical fatigue; Physical and mental fatigue; Physical overwork; Functional asthenic conditions; Chronic fatigue; Chronic asthenic conditions

T30 Thermal and chemical burns of unspecified site: Pain syndrome with burns; Pain in burns; Pain with burns; Sluggishly healing post-burn wounds; Deep burns with a wet scab; Deep burns with abundant compartments; Deep burn; Laser burn; Burn; Burn of rectum and perineum; Burn with mild exudation; Burn disease; Burn injury; Superficial burn; Superficial burn of I and II degree; Superficial skin burns; After-burn trophic ulcer and wound; Post-burn complication; Loss of fluid in burns; Sepsis burn; Thermal burns; Thermal skin lesions; Thermal burn; Trophic after-burn ulcers; Chemical burn; Surgical burn

T79.3 Post-traumatic wound infection, not elsewhere classified: Inflammation after surgery and trauma; Inflammation after trauma; Secondary infection of skin and mucous membrane damage; Deep Wounds; Purulent wound; Purulent-necrotic phase of wound process; Purulent-septic diseases; Purulent Wounds; Purulent wounds with the presence of deep cavities; Granulating wounds of small size; Disinfection of purulent wounds; Wound infections; Infections wound; Infection of wounds; Infected and non-healing wound; Infected postoperative wound; Infected wound; Infected Skin Wounds; Infected burns; Infected Wounds; Suppurating postoperative wounds; Extensive purulent-necrotic process of soft tissues; Burn infections; Burn infection; Perioperative infection; Poorly healing infected wound; Postoperative and purulent-septic wound; Postoperative wound infection; Wound infection; Wound botulism; Wound infections; Wounds of purulent; Wounds infected; Reinfection of granulating wounds; Sepsis posttraumatic

Z100 * CLASS XXII Surgical practice: Abdominal surgery; adenomectomy; Amputation; Coronary angioplasty; Angioplasty of the carotid arteries; Antiseptic skin treatment for wounds; Antiseptic Hand; Appendectomy; atherectomy; Balloon coronary angioplasty; Vaginal hysterectomy; The coronary bypass; Interventions in the vagina and cervix; Interventions on the bladder; Intervention in the mouth; Restoration and reconstructive surgery; Hand hygiene of medical personnel; Gynecologic surgery; Gynecological intervention; Gynecological surgery; Hypovolemic shock during operations; Disinfection of purulent wounds; Disinfection of wounds edges; Diagnostic intervention; Diagnostic procedures; Cervical Diathermocoagulation; Long-surgery; Replacing the fistula catheters; Infection in orthopedic surgery; Artificial heart valve; cystectomy; Short-term outpatient surgery; Short-term operation; Short surgical procedures; Krikotireotomiya; Blood loss during surgery; Bleeding during surgery and in the postoperative period; Kuldotsentez; laser photocoagulation; laser coagulation; retinal laser coagulation; Laparoscopy; Laparoscopy in Gynecology; CSF fistula; Small gynecological operations; Small surgical procedures; Mastectomy and subsequent plastic; mediastinotomy; Microsurgical operations on the ear; Mukogingivalnye operation; suturing; Minor surgery; neurosurgical operation; Immobilization of the eyeball in ophthalmic surgery; testectomy; pancreatectomy; Perikardektomiya; The period of rehabilitation after surgery; The period of convalescence after surgery; Percutaneous transluminal coronary angioplasty; Pleural thoracentesis; Pneumonia postoperative and posttraumatic; Preparation for surgical procedures; Preparation for surgery; Preparation of the surgeon's hands before surgery; Preparation of the colon for surgical procedures; Postoperative aspiration pneumonia in neurosurgical and thoracic surgery; Postoperative nausea; Postoperative bleeding; postoperative granuloma; postoperative shock; The early postoperative period; myocardial revascularization; Radiectomy; gastric Resection; bowel resection; uterine Resection; liver Resection; enterectomy; Resection of part of the stomach; Reocclusion of the operated vessel; Bonding tissues during surgical procedures; Removal of sutures; Condition after eye surgery; Condition after surgery; Condition after surgery in the nasal cavity; Condition after gastrectomy; Status after resection of the small intestine; Condition after tonsillectomy; Condition after removal of the duodenum; Condition after phlebectomy; Vascular surgery; Splenectomy; Sterilization of surgical instruments; Sterilization of surgical instruments; sternotomy; Dental surgery; Dental intervention in periodontal tissues; strumectomy; Tonsillectomy; Thoracic surgery; Thoracic surgery; total gastrectomy; Transdermal intravascular coronary angioplasty; Transurethral resection; Turbinektomiya; Removal of a tooth; cataract surgery; Removal of cysts; tonsillectomy; Removal of fibroids; Removing the mobile primary teeth; Removing polyps; Removing broken tooth; Removal of the uterus body; Removal of sutures; Fistula likvoroprovodyaschih ways; Frontoetmoidogaymorotomiya; Surgical infection; Surgical treatment of chronic limb ulcers; Surgery; The surgery in the anal area; The surgery on the colon; Surgical practice; The surgical procedure; Surgical interventions; Surgery on the gastrointestinal tract; Surgical procedures on the urinary tract; Surgical procedures on the urinary system; Surgical intervention of the genitourinary system; Surgical procedures on the heart; Surgical manipulation; surgery; Surgery on the veins; Surgical intervention; Vascular surgery; Surgical treatment of thrombosis; Surgery; cholecystectomy; Partial gastric resection; hysterectomy; Percutaneous transluminal coronary angioplasty; Percutaneous transluminal angioplasty; Coronary artery bypass; tooth Extirpation; Extirpation of milk teeth; pulpectomy; pulsative cardiopulmonary bypass; tooth Extraction; teeth Extraction; cataract extraction; Electrocoagulation; endourological intervention; episiotomy; Etmoidotomiya; Complications after tooth extraction

Z40 Preventive Surgery: Inhalational Anesthesia; Intratracheal Intubation; Intubation of the trachea; Surface anesthesia in ophthalmology

Z50.2 Rehabilitation for alcoholism: Alcoholism during remission

Z50.3 Rehabilitation for drug addiction: Benzodiazepine dependence

Z51.0 Radiotherapy course: Supplement to external radiation therapy; Local X-Ray Irradiation; Radiation therapy; Brain edema associated with radiation therapy; Lesion in radiation therapy; Radiotherapy

Z51.1 Chemotherapy for neoplasm: Cystitis hemorrhagic, caused by cytostatics; Urotoxicity of cytostatics

Z54.0 Recovery period after surgical intervention: Conditions after neurosurgical operations; Conditions after removal of gallstones; Conditions after surgery; Restorative period after surgical interventions; Recovery period after operations; The rehabilitation period after surgical interventions; The rehabilitation period after surgical operations; Reconvalence after surgery; Reconvalence after surgical intervention; Reconvalescence in the postoperative period; Recovery period after surgery in front of eyes; Period after hemorrhoidectomy; Postoperative period; Period of postoperative rehabilitation; The rehabilitation period after injuries

Z73.6 Restrictions on activities caused by disability: General weakness; Mental fatigue; Syndrome of decrease in working capacity and physical overstrain; Decreased motor activity; Decreased performance; Decreased physical performance; Reduced performance; Decreased efficiency of the body; Reduced performance in extreme situations; Weakness

Z98.8 Other specified post-surgical conditions: Purulent complications in the postoperative period; Suppurative complications of surgery; Postoperative liver dysfunction; Postoperative vomiting; Postoperative complications; Postoperative period; Early postoperative period

Composition

Powder for solution for intramuscular injection 1 fl.

active substance: Aminodihydrophthalazinedione sodium (GalavitŽ) 50 mg; 100 mg

Suppositories rectal 1 supp.

active substance: Aminodihydrophthalazinedione sodium (GalavitŽ) 50 mg; 100 mg

Auxiliary substances: Witepsol H15 (glycerides of fatty acids) - 575 mg; Witepsol W35 (glycerides of fatty acids) - 575 mg

Tablets Sublingual 1 tab.

active substance: Aminodihydrophthalazinedione sodium (GalavitŽ) 25 mg

Auxiliary substances: sorbitol - 315 mg; Starch - 140 mg; Lactose - 100 mg; Calcium stearate - 5 mg; Talcum - 15 mg; Racetenol (menthol) 0.1 mg

Description of dosage form

Suppositories: from white to white with a yellowish hue of color, torpedo shape without visible inclusions on the longitudinal section.

Tablets: white with a yellowish tinge, biconvex, without risks, with a smell of menthol.

Pharmachologic effect

Mode of action - anti-inflammatory, immunomodulating.

Pharmacodynamics

Suppositories rectal, 50 mg, 100 mg; Sublingual tablets

The mechanism of action of the drug is associated with the ability to affect the functional metabolic activity of macrophages.

In inflammatory diseases, the drug reversibly for 6-8 hours inhibits the excessive synthesis of TNF, IL-1 and other pro-inflammatory cytokines, active forms of oxygen by hyperactivated macrophages, determining the degree of inflammatory reactions, their cyclicity, and the severity of intoxication. Normalization of the functional state of macrophages leads to the restoration of the antigen presenting and regulating function of macrophages, to a decrease in the level of autoaggression. Stimulates the bactericidal activity of neutrophilic granulocytes, enhancing phagocytosis and increasing the nonspecific resistance of the organism to infectious diseases.

Powder for solution for IM administration

The mechanism of action of the drug is associated with its ability to affect the functional and metabolic activity of phagocytic cells (monocytes / macrophages, neutrophils, natural killers). In addition, GalavitŽ normalizes antibody formation, indirectly stimulates the production of endogenous interferons (IFN-α, IFN-γ).

In inflammatory diseases, the drug reversibly for 6-8 hours inhibits excessive synthesis of hyperactivated macrophages TNF-α, IL-1, IL-6 and other pro-inflammatory cytokines, active forms of oxygen, whose level determines the degree of inflammatory reactions, their cyclicity, as well as the severity of intoxication and Level of oxidative stress. Normalization of the functional state of macrophages leads to the restoration of the antigen presenting and regulating function of macrophages, to a decrease in the level of autoaggression. Stimulates the bactericidal activity of neutrophilic granulocytes, enhancing phagocytosis and increasing the nonspecific resistance of the organism to infectious diseases.

Pharmacokinetics

It is excreted from the body, mainly through the kidneys. After IM injection, T1 / 2 - 30-40 minutes; After rectal administration - 40-60 min; After the sublingual - 30 min. The main pharmacological effects are observed for 72 hours.

Indications Galavit

Powder for solution for IM administration

As an immunomodulatory and anti-inflammatory drug in the complex therapy of immunodeficient conditions in adults and adolescents from the age of 12:

Peptic ulcer of the stomach and duodenum;

Viral hepatitis;

Chronic recurrent diseases caused by the herpes virus;

Diseases caused by the human papillomavirus;

Infectious-inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingo-oophoritis, endometritis);

Purulent-inflammatory diseases of the pelvic organs;

Postoperative rehabilitation of patients with uterine myoma;

Complications of the postoperative period in women of reproductive age;

Postoperative purulent-septic complications and their prophylaxis (including in cancer patients);

Chronic recurrent furunculosis, erysipelas;

Asthenic conditions, neurotic and somatoform disorders, reduced physical performance (including athletes);

Mental, behavioral and post-drug disorders in alcohol and drug dependence;

Inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal disease.

In adults and adolescents with 12 years in monotherapy:

Acute and chronic infectious-inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and / or diarrhea;

Chronic urogenital infections, incl. At carrying out immunorehabilitation measures during the inter-recessive period with the purpose of maintaining clinical remission.

As an immunomodulating and anti-inflammatory drug in the complex therapy of immunodeficient conditions in children older than 6 years:

Purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);

Frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent acute respiratory infections, bronchitis, pneumonia, chronic tonsillitis, chronic otitis media, chronic adenoiditis).

Suppositories rectal, 50 mg

As an immunomodulatory and anti-inflammatory drug in complex therapy in children aged 6-12 years:

Infectious intestinal diseases, accompanied by intoxication and / or diarrhea;

Peptic ulcer of the stomach and duodenum;

Viral hepatitis;

Chronic recurrent diseases caused by the herpes virus;

Diseases caused by the papilloma virus;

Purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);

Asthenic conditions, neurotic and somatoform disorders, reduced physical performance;

Postoperative purulent-septic complications and their prophylaxis (including in cancer patients);

Treatment and prevention of urogenital infections of bacterial and viral etiology;

Inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal disease;

Frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent ARI, bronchitis, pneumonia, chronic tonsillitis, chronic otitis media, chronic adenoiditis);

Prevention of influenza and acute respiratory infections.

Suppositories rectal, 100 mg

As an immunomodulating and anti-inflammatory drug in the complex therapy of immunodeficient conditions in adults and adolescents over 12 years of age:

Infectious intestinal diseases, accompanied by intoxication and / or diarrhea;

Peptic ulcer of the stomach and duodenum;

Viral hepatitis;

Chronic recurrent diseases caused by the herpes virus;

Diseases caused by the papilloma virus;

Infectious-inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingo-oophoritis, endometritis);

Purulent-inflammatory diseases of the pelvic organs;

Postoperative rehabilitation of patients with uterine myoma;

Complications of the postoperative period in women of reproductive age;

Postoperative purulent-septic complications and their prophylaxis (including in cancer patients);

Chronic recurrent furunculosis, erysipelas;

Asthenic conditions, neurotic and somatoform disorders, reduced physical performance (including athletes);

Mental, behavioral and post-drug disorders in alcohol and drug dependence;

Inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal disease;

Nonspecific prevention and treatment of influenza and acute respiratory infections.

Tablets for oral hygiene

As an immunomodulating and anti-inflammatory drug in the complex therapy of immunodeficient conditions in adults and adolescents over 12 years of age:

Infectious intestinal diseases, accompanied by intoxication and / or diarrhea;

Peptic ulcer of the stomach and duodenum;

Viral hepatitis;

Chronic recurrent diseases caused by the herpes virus;

Diseases caused by the human papillomavirus;

Infectious-inflammatory urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis, acute and chronic salpingo-oophoritis, endometritis);

Purulent-inflammatory diseases of the pelvic organs;

Postoperative rehabilitation of patients with uterine myoma;

Complications of the postoperative period in women of reproductive age;

Purulent surgical diseases (burn lesions, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy);

Postoperative purulent-septic complications and their prophylaxis (including in cancer patients);

Chronic recurrent furunculosis, erysipelas;

Asthenic conditions, neurotic and somatoform disorders, reduced physical performance (including athletes);

Mental, behavioral and post-drug disorders in alcohol and drug dependence;

Inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal disease;

Contraindications

Powder for solution for IM administration

Individual intolerance;

pregnancy;

lactation;

Children under 6 years of age (no clinical experience of use).

Suppositories rectal, 50 mg

Individual intolerance;

Children's age till 6 years.

Suppositories rectal, 100 mg

Individual intolerance;

pregnancy;

lactation.

Tablets for oral hygiene

Individual intolerance;

pregnancy;

lactation.

Side effects

In rare cases, allergic reactions are possible.

Interaction

With simultaneous use, it is possible to reduce the dose of antibiotics. Cases of incompatibility with other drugs have not been noted.

Dosing and Administration

IM, rectally, sublingually.

Powder for solution for IM administration

Before the introduction, the drug is diluted in 2 ml of water for injection or 0.9% solution of sodium chloride. The method of administration, dose and duration of application are chosen by the doctor depending on the diagnosis, severity of the disease, age of the patient.

With peptic ulcer of the stomach and duodenum: in the acute period - 2 days for 200 mg once a day, then for 100 mg with an interval of 72 hours. The course - 15-25 injections. In the chronic period - 5 days of 100 mg once a day, then 100 mg after 72 hours. Course - 20 injections.

In viral hepatitis: the initial dose is 200 mg once, then 100 mg 2 times a day until the symptoms of intoxication and inflammation stop. The subsequent continuation of the course - 100 mg at 72 h intervals. The course - 20-25 injections.

In chronic relapsing diseases caused by the herpes virus - 100 mg daily 5 injections, then 100 mg every other day 15 injections.

In diseases caused by the papilloma virus: 5 days to 100 mg once a day, then 100 mg every other day 15 injections. Course - 20 injections.

With urogenital diseases - urethritis chlamydial and trichomonas etiology, chlamydial prostatitis: 1 day of 100 mg twice, then 100 mg every other day. Course - 10-15 injections (depending on the severity of the pathological process).

With salpingo-oophoritis, endometritis: in the acute period - 2 days at 200 mg once a day, then at 100 mg with an interval of 72 hours, the duration of use depends on the severity of the disease. A total of 20 injections per course. In the chronic period - 5 days of 100 mg once a day, then 100 mg every 72 hours. Course - 20 injections.

In acute and chronic purulent diseases of the pelvic organs: in the acute period - 1 day 200 mg once, 3 days for 100 mg daily, then 100 mg every other day 5 injections. Course - 10 injections. In the chronic period - 5 days to 100 mg once a day, then 100 mg every 72 hours. Course - 20 injections.

For postoperative rehabilitation of patients with uterine myoma and with postoperative complications in women of reproductive age: 5 days to 100 mg once a day, then 100 mg every other day. Course - 15 injections.

For the prevention and treatment of postoperative infectious complications in the pre- and postoperative period (including cancer patients): 100 mg once a day, 5 injections before surgery, 5 injections after surgery, 100 mg every other day, and 5 injections of 100 Mg with an interval of 72 hours. In severe cases, the initial dose is 200 mg once or twice a day for 100 mg. Course - 20 injections.

With chronic recurrent furunculosis, erysipelas: 5 days to 100 mg once a day, then 100 mg every other day. Course - 20 injections.

In asthenic conditions, neurotic and somatoform disorders, mental, behavioral and post-abstinence disorders, in patients with alcohol and drug dependence: 5 days of 100 mg daily, then 100 mg after 72 hours. Course - 15-20 injections.

To improve physical performance: 100 mg every other day 5 injections, then 100 mg after 72 hours, the course - up to 20 injections.

With inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal diseases: the initial dose is 100 mg daily 5 injections, then 100 mg with an interval of 72 hours. Course - 15 injections.

In monotherapy in adults and adolescents with 12 years

In acute and chronic infections and inflammatory diseases of the gastrointestinal tract, accompanied by intoxication and / or diarrhea, 200 mg once, then 100 mg 2 times a day until symptoms of intoxication stop. Perhaps the subsequent continuation of the course of 100 mg with an interval of 72 hours. Course - 20-25 injections.

With chronic urogenital infections, incl. At carrying out immunorehabilitation measures during the inter-recessive period with the purpose of maintaining clinical remission: 100 mg every other day by a course of 10 injections.

Children older than 6 years

In purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy): children from 6 to 11 years - 1 injection 50 mg daily - 5 days, then 1 injection 50 mg every other day Within 10-15 days. Course - 10-15 injections; Children aged 12-18 years - treatment is carried out according to the same scheme in the form of IM injections of 100 mg. When dressing, external application of the GalavitŽ preparation in the form of dressings with sterile wipes moistened with 1% GalavitŽ solution in water for injection (in bandages with a talker or water-soluble ointment dressings) is desirable.

With frequent recurrent diseases of the respiratory tract and ENT organs of bacterial and viral etiology (frequent acute respiratory infections, bronchitis, pneumonia, chronic tonsillitis, chronic otitis, chronic adenoiditis): children from 6 to 11 years - 1 injection 50 mg daily for 5 days, Then 50 mg once a day every other day for 10-15 days. Course - 10-15 injections. Children aged 12-18 years - treatment according to the same scheme in the form of IM injections of 100 mg.

Suppositories rectal, 100 mg

The suppository is released from the contoured package and then injected into the rectum. Pre-recommended to relieve the intestines.

The dose and duration of the drug depend on the nature, severity and duration of the disease.

In acute infectious intestinal diseases, accompanied by diarrheal syndrome: the initial dose is 2 supp. Once, then 1 soup. 2 times a day until relief of symptoms of intoxication. Perhaps the subsequent continuation of the course for 1 soup. With an interval of 72 hours. Course - 20-25 soups.

With peptic ulcer of the stomach and duodenum: in the acute period - 2 days for 2 soups. 1 time per day, then 1 soup. With an interval of 72 hours. Course - 15-25 soups. In the chronic period - 5 days to 1 supp. 1 time per day, then 1 soup. After 72 hours. Course - 20 soups.

With viral hepatitis: the initial dose is 2 supp. Once, then 1 soup. 2 times a day until the relief of symptoms of intoxication and inflammation. The subsequent continuation of the course - 1 soup. With an interval of 72 hours. Course - 20-25 soups.

With chronic relapsing diseases caused by the herpes virus - 1 soup. Daily - 5 soups, then 1 soup. In a day - 15 soups.

In diseases caused by the papilloma virus, 5 days to 1 supp. 1 time per day, then 1 soup. in one day. Course - 20 soups.

With urogenital diseases (urethritis chlamydial and trichomonas etiology, chlamydial prostatitis): 1 day to 1 soup. Twice, then 1 soup. - in one day. The rate is 10-15 soup. (Depending on the severity of the pathological process).

With salpingo-oophoritis, endometrium: in acute period - 2 days for 2 soups. 1 time per day, then 1 soup. With an interval of 72 hours. In a chronic period - 5 days for 1 supp. 1 time per day, then 1 soup. Every 72 hours. Course - 20 soups.

In acute and chronic purulent diseases of the pelvic organs: in acute period - 1 day for 2 soups. Once, 3 days for 1 supp. Daily, then 1 soup. In a day - 5 days. The course is 10 soup. In the chronic period - 5 days to 1 supp. 1 time per day, then 1 soup. Every 72 hours. Course - 20 soups.

For postoperative rehabilitation of patients with uterine myoma and with complications of the postoperative period in women of reproductive age: 5 days to 1 supp. 1 time per day, then 1 soup. in one day. Course - 15 soups.

For the prevention and treatment of surgical complications in the pre- and postoperative period (including cancer patients): 1 supp. Once a day - 5 soups. Before surgery, 5 soups. - 1 supp. After surgery every other day and 5 supp. - 1 supp. With an interval of 72 hours. In severe cases, the initial dose is 2 supp. Once or twice a day for 1 soup. Course - 20 soups.

With asthenic conditions, neurotic and somatoform disorders, mental, behavioral and post-abstinence disorders, in patients with alcohol and drug dependence: 5 days to 1 supp. Daily, then 1 soup. After 72 hours. Course - 15-20 soup.

To improve physical performance: 1 soup. Every other day - 5 soup., Then 1 soup. After 72 hours, the course - up to 20 soups.

In inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal diseases: the initial dose - 1 soup. Daily - 5 soups, then 1 soup. With an interval of 72 hours. Course - 15 soups.

For non-specific prevention and treatment of influenza and acute respiratory infections: 1 supp. 1 per day. Course - 5 days.

Suppositories rectal, 50 mg

The suppository is released from the contoured package and then injected into the rectum. Pre-recommended to relieve the intestines.

In acute infectious intestinal diseases, accompanied by diarrheal syndrome: the initial dose is 2 supp. 50 mg once, then 1 soup. 2 times a day until relief of symptoms of intoxication. Perhaps the subsequent continuation of the course for 1 soup. With an interval of 72 hours. Course - 20 soups.

With chronic recurrent diseases caused by the herpes virus: 1 soup. Daily for 5 days, then 1 soup. in one day. Course - 15 soups.

In diseases caused by the papilloma virus: 5 days to 1 supp. 1 time per day, then 1 soup. in one day. Course - 20 soups.

With purulent surgical diseases (burn lesions, recurrent furunculosis, chronic osteomyelitis, gangrenous appendicitis with omentitis, purulent pleurisy): 1 supp. Daily - 5 days, then 1 soup. Every other day for 10 days.

At asthenic conditions, neurotic and somatoform disorders: 5 days to 1 supp. Daily, then 1 soup. After 72 hours. Course - 15 soup.

To improve physical performance: 1 soup. Through the day, the course is 5 soups.

For the prevention and treatment of surgical complications in the pre- and postoperative period (including cancer patients): 1 supp. Once a day - 5 soups. Before surgery, 5 - after surgery for 1 supp. Every other day and 5 soups. With an interval of 72 hours. In severe cases, the initial dose is 2 soups. Once or twice a day for 1 soup. Course - 20 soups.

In the treatment and prevention of urogenital infections of bacterial and viral etiology: 1 day to 1 supp. 2 times a day, then 1 soup. in one day. The rate is 10-15 soup. (Depending on the severity of the pathological process).

For the prevention of influenza and acute respiratory infections - 1 soup. 1 per day. The course is 5 soup.

Tablets for oral hygiene

According to 1 table. Daily up to 4 times a day or 2 tablets. Daily up to 2 times a day, depending on the diagnosis and severity of the disease.

In acute infectious intestinal diseases, accompanied by diarrhea syndrome: the initial dose is 2 tablets. Once, then on 1 tab. 3-4 times a day until relief of symptoms of intoxication within 3-5 days.

With peptic ulcer of the stomach and duodenum: in the acute period - the first 2 days - 1 table. 4 times a day, then every 3 days for 1 table. 4 times a day, the course - 2-3 weeks. In the chronic period - 5 days to 1 table. 4 times a day, then every 3 days for 1 table. 4 times a day up to 3 weeks.

With viral hepatitis of different etiology: in the acute period of the disease, the initial dose is 2 tablets. 2 times a day until the relief of symptoms of intoxication and inflammation. Perhaps the subsequent continuation of the course of 1 tab. 4 times a day every 3 days with a course up to 2-3 weeks.

With chronic recurrent diseases caused by the herpes virus: 1 tab. 4 times a day for 10 days. Then on 1 tab. 4 times a day every other day for 10 days.

In diseases caused by human papillomavirus: 5 days to 1 table. 4 times a day, then 1 table. 4 times a day every other day up to 2-3 weeks.

With urogenital diseases (urethritis of chlamydial and trichomonas etiology, chlamydial prostatitis): on the first day - 2 times 2 tablets, then 1 table. 4 times a day every other day up to 2 weeks (depending on the severity of the pathological process).

With salpingo-oophoritis, endometrium: in acute period - 2 days, 2 tablets. 2 times a day, then 1 table. 4 times a day every 3 days for 3 weeks. In the chronic period - 5 days to 1 table. 4 times a day, then 1 table. 4 times a day every 3 days with a course up to 2-3 weeks.

In acute and chronic purulent diseases of the pelvic organs: in the acute period on the first day - 2 tablets. 2 times a day, then 3 days for 1 table. 4 times a day, then 1 table. 4 times a day every other day for 10 days. In the chronic period - 5 days to 1 table. 4 times a day, then 3-4 tablets. Every 3 days to 3 weeks.

For postoperative rehabilitation of patients with uterine myoma and with complications of the postoperative period in women of reproductive age: 5 days to 1 table. 4 times a day, then 1 table. 4 times a day every other day up to 2 weeks.

With purulent surgical diseases (burn lesions, chronic osteomyelitis, gangrenous appendicitis with omentitis, peritonitis, purulent pleurisy): 4 times a day for 1 table. For 5 days, then 1 table. 4 times a day, up to 15 days.

For the prevention and treatment of surgical complications in the pre- and postoperative period (including in cancer patients): 1 table. 4 times a day for 5 days before the operation, within 10 days after the operation, 1 table. 4 times every other day and for 3 weeks for 1 table. 4 times in 3 days. In severe disease - on the first day of 2 tables. 2 times a day.

With chronic recurrent furunculosis, erysipelas: 5 days to 1 table. 4 times a day, then 1 table. 4 times a day, up to 3 weeks.

With asthenic conditions, neurotic and somatoform disorders, mental, behavioral and post-abstinence disorders, in patients with alcohol and drug dependence: 5 days to 1 table. 4 times a day, then 1 table. 4 times every 3 days for 3 weeks.

To improve physical performance: 1 tab. 4 times every other day for 10 days, then 1 table. 4 times a day through 3 days course up to 3 weeks.

With inflammatory diseases of the mucous membrane of the oral cavity and throat, periodontal diseases: the initial dose is 1 table. 4 times a day for 5 days, then 1 table. 4 times a day through 3 days course up to 3 weeks.

For the prevention of acute respiratory infections and influenza: 1 tab. 2 times a day with a course of 5-10 days.

Special instructions

Influence on the ability to drive vehicles and work with machinery.

Powder for the preparation of solution for the IM introduction. There is no information.

Release form

Powder for the preparation of solution for intramuscular injection. In a vial, 50 mg, 100 mg. 3 or 5 fl. In a cardboard box.

Suppositories rectal, 50 mg, 100 mg. In the outline of the cell, 5 pcs. 1 or 2 contour packs in a cardboard bundle.

Tablets are sublingual, 25 mg. In the outline of the cell packaging of PVC film and aluminum foil, 10 or 20 pcs. 1, 2, 3 or 4 contour packs in a cardboard bundle. 10, 20, 30, 40 or 50 contour packs in a group package.

Manufacturer

OOO "Salvim". Russia, Moscow

Conditions of supply of pharmacies

Powder for the preparation of solution for the IM introduction. On prescription. Suppositories rectal, tablets sublingual. Without recipe.

Storage conditions of the drug Galavit

In the dark place at a temperature of 15-25 ° C.

Keep out of the reach of children.

The shelf life of the drug Galavit

Sublingual tablets 25 mg - 3 years.

Powder for the preparation of solution for intramuscular injection 50 mg - 4 years.

Powder for solution for intramuscular injection 100 mg - 4 years.

Rectal suppositories 50 mg - 3 years.

Suppositories rectal 100 mg - 3 years.

Do not use beyond the expiration date printed on the package.

Instructions

Instruction for use: Galavit

Popular postslike this

You may also like